Hedgehog pathway signaling in cervical carcinoma and outcome after chemoradiation

Cancer

Volumn 118, Issue 12, 2012, Pages 3105-3115

  Chaudary, Naz ^a   Pintilie, Melania ^a   Hedley, David ^a,b   Fyles, Anthony W ^a,b   Milosevic, Michael ^a,b   Clarke, Blaise ^b   Hill, Richard P ^a,b   Mackay, Helen ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Cervical cancer; Chemoradiation; Gene expression; Hedgehog pathway; Heterogeneous

Indexed keywords

CISPLATIN;

ADULT; AGE; AGED; ARTICLE; BRACHYTHERAPY; CANCER RECURRENCE; CANCER RELAPSE; CANCER STAGING; CHEMORADIOTHERAPY; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DOWN REGULATION; EXTERNAL BEAM RADIOTHERAPY; FEMALE; FRIZZLED FAMILY RECEPTOR GENE; FROZEN SECTION; GENE; GENE EXPRESSION PROFILING; GLI1 GENE; HUMAN; HUMAN TISSUE; HYPOXIA; INDIAN HEDGEHOG GENE; LOCAL RECURRENCE FREE SURVIVAL; MAJOR CLINICAL STUDY; MULTIGENE FAMILY; ONCOGENE; OVERALL SURVIVAL; PATCHED 1 GENE; PATCHED 2 GENE; PELVIS LYMPH NODE; PRIMARY TUMOR; PRIORITY JOURNAL; PROGNOSIS; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SMOOTHENED GENE; SONIC HEDGEHOD GENE; TISSUE PRESSURE; TREATMENT OUTCOME; TUMOR BIOPSY; TUMOR DIFFERENTIATION; TUMOR HYPOXIA; TUMOR VOLUME; UPREGULATION; UTERINE CERVIX CARCINOMA;

ADULT; AGED; CELL HYPOXIA; CHEMORADIOTHERAPY; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION; HEDGEHOG PROTEINS; HUMANS; MIDDLE AGED; PARTIAL PRESSURE; SIGNAL TRANSDUCTION; UP-REGULATION; UTERINE CERVICAL NEOPLASMS;

EID: 84861875422     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.26635     Document Type: Article

References (41)

1. Jemal A, Siegal R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin. 2009;59:225-249.
2. Waggoner SE. Cervical cancer. Lancet. 2003;361:2217-2225. (Pubitemid 36782559)
3. National Cancer Institute. Cervical Cancer (PDQ): Treatment. Bethesda, MD: National Cancer Institute; 2005. Available at: http://www.cancer.gov/ cancertopics/pdq/treatment/cervical/HealthProfessional/page4. Accessed May 2011.
4. Chemoradiotherapy for Cervical Cancer Meta-analysis Collaboration. Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: individual patient data metaanalysis. Cochrane Database Syst Rev. 2010;(1):CD008285.
5. Moore DH, Blessing JA, McQuellon RP, et al. Phase III study of cisplatin with or without paclitaxel in stage IVB recurrent or persistent squamous carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol. 2004;22:3113-3119. (Pubitemid 41103724)
6. Long HJ, Bundy BN, Grendys EC, et al. Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group study. J Clin Oncol. 2005;23:4626-4633. (Pubitemid 46224065)
7. Monk BJ, Sill M, McMeekin DS, et al. A randomized phase III trial of 4 cisplatin (CIS) containing doublet combinations in stage IVB, recurrent or persistent cervical carcinoma: a Gynecologic Oncology Group (GOG) study J Clin Oncol. 2008;26(May 20 suppl). Abstract LBA5504.
8. Monk BJ, Sill MW, Burger RA, Gray HJ, Buekers TE, Roman LD. Phase II trial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol. 2009;27:1069-1074.
9. Goncalves A, Fabbro M, Lhomme C, et al. A phase II trial to evaluate gefitinib as second- or third-line treatment in patients with recurring locoregionally advanced or metastatic cervical cancer. Gynecol Oncol. 2008;108:42-46.
10. Ingham PW, McMahon AP. Hedgehog signaling in animal development: paradigms and principles. Genes Dev. 2001;15:3059-3087. (Pubitemid 33115673)
11. Hooper JE, Scott MP. Communicating with hedgehogs. Nat Rev Mol Cell Biol. 2005;6:306-317. (Pubitemid 40516897)
12. Caro I, Low JA. The role of the hedgehog signaling pathway in the development of basal cell carcinoma and opportunities for treatment. Clin Cancer Res. 2010;16:3335-3339.
13. Liao X, Siu MKY, Au CWH, et al. Aberrant activation of hedgehog signaling pathway in ovarian cancers: effect on prognosis cell invasion and differentiation. Carcinogenesis. 2009;30:131-140.
14. Feng Y-Z, Showaza T, Miyamoto et al. Over expression of hedgehog signaling molecules and its involvement in the proliferation of endometrial carcinoma cells. Clin Cancer Res. 2007;13:1389-1398. (Pubitemid 46450427)
15. ten Haaf A, Bektas N, von Serenyi S, et al. Expression of the glioma-associated oncogene homolog (GLI) 1 in human breast cancer is associated with unfavorable overall survival [serial online]. BMC Cancer. 2009;9:298.
16. Hidalgo M. Pancreatic cancer. N Engl J Med. 2010;362:1605-1617.
17. Berman DM, Karhadkar SS, Maitra A, et al. Widespread requirement for hedgehog ligand stimulation in growth of digestive tract tumors. Nature. 2003;431:846-851. (Pubitemid 37351469)
18. Thayer SP, di Magliano MP, Heiser PW, et al. Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis. Nature. 2003;425:851-856. (Pubitemid 37355945)
19. Yauch RL, Gould SE, Scales SJ, et al. A paracrine requirement for hedgehog signaling in cancer. Nature. 2008;455:406-410.
20. Curran T, Hg JMY. Hedgehog's other trick. Nature. 2008;455:293-294.
21. Theunissen JW, de Sauvage FF. Paracrine hedgehog signaling in cancer. Cancer Res. 2009;69:6007-6010.
22. Wang G, Zhang Z, Xu Z. Activation of the sonic hedgehog signaling controls human pulmonary arterial smooth muscle cell proliferation in response to hypoxia. Biochim Biophys Acta. 2010;1803:1359-1367.
23. Bijlsma MF, Groot AP, Oduro JP, et al. Hypoxia induces a hedgehog response mediated by HIF-1alpha. J Cell Mol Med. 2009;13(8B):2053-2060.
24. Onishi H, Kai M, Odate S, et al. Hypoxia activates the hedgehog signaling pathway in a ligand-independent manner by upregulation of Smo transcription in pancreatic cancer. Cancer Sci. 2011;102:1144-1150.
25. Rofstad EK, Sundfor K, Lyng H, Trope CG. Hypoxia-induced treatment failure in advanced squamous cell carcinoma of the uterine cervix is primarily due to hypoxiainduced radiation resistance rather than hypoxia-induced metastasis. Br J Cancer. 2010;83:354-359.
26. Fyles A, Milosevic M, Hedley D, et al. Tumor hypoxia has independent predictor impact only in patients with node-negative cervix cancer. J Clin Oncol. 2002;20:680-687. (Pubitemid 34111374)
27. Milosevic M, Fyles A, Hedley D, et al. Interstitial fluid pressure predicts survival in patients with cervix cancer independent of clinical prognostic factors and tumor oxygen measurements. Cancer Res. 2001;61:6400-6405. (Pubitemid 32783245)
28. Hockel M, Vorndran B, Schlenger K, Baussmann E, Knapstein PG. Tumor oxygenation: a new predictive parameter in locally advanced cancer of the uterine cervix. Gynecol Oncol. 1993;51:141-149. (Pubitemid 24020354)
29. Sims-Mourtada J, Izzo JG, Apiarnthanarax S, et al. Hedgehog: an attribute to tumor regrowth after chemoradiotherapy and a target to improve radiation response. Clin Cancer Res. 2006;12:6565-6572. (Pubitemid 44799732)
30. Yoshikawa R, Nakano Y, Tao L, et al. Hedgehog signal activation in oesophageal cancer patients undergoing neoad-juvant chemoradiotherapy. Br J Cancer. 2008;98:1670-1674. (Pubitemid 351684687)
31. Chung C, Dignam JJ, Hammond EM, et al. Glioma-associated oncogene family zinc finger 1 expression and metastasis in patients with head and neck squamous cell carcinoma treated with radiation therapy (RTOG 9003). J Clin Oncol. 2011;29:1326-1334.
32. Hedley D, Pintilie M, Woo J, et al. Carbonic anhydrase IX expression, hypoxia, and prognosis in patients with uterine cervical carcinomas. Clin Cancer Res. 2001;61:639-6349.
33. Iakovlev VV, Pintilie M, Morrison A, Fyles AW, Hill RP, Hedley DW. Effect of distributional heterogeneity on the analysis of tumor hypoxia based on carbonic anhydrase IX. Lab Invest. 2007;87:1206-1217. (Pubitemid 350126705)
34. Hricak H, Gastonis C, Chi DS, et al. Role of imaging in pretreatment evaluation of early invasive cancer: results of the intergroup study American College of Radiology Imaging Network 6651-Gynecologic Oncology Group 183. J Clin Oncol. 2005;23:9329-9337.
35. Choi HJ, Kim SH, Seo SS, et al. MRI for pretreatment lymph node staging in uterine cervical cancer. AJR Am J Roentgenol. 2006;187:W538-W543.
36. Fyles A, Milosevic M, Pintilie M, et al. Long-term performance of interstital fluid pressure and hypoxia as prognostic factors in cervix cancer. Radiother Oncol. 2006;80:132-137. (Pubitemid 44314013)
37. Bachtiary B, Boutros PC, Pintilie M, et al. Gene expression profiling in cervical cancer: an exploration of intratumor heterogeneity. Clin Cancer Res. 2006;12:5632-5640. (Pubitemid 44629589)
38. Dempter AP, Laird NM, Rubin DB. Maximum likelihood from incomplete data via EM algorithm. J R Stat Soc B. 1977;39:1-38.
39. Xuan YH, Soon Jung H, Coi Y-L, et al. Enhanced expression of hedgehog signaling molecules in squamous cell carcinoma of uterine cervix and its precursor lesions. Mod Pathol. 2006;19:1139-1147. (Pubitemid 44106730)
40. Pereira Tde A, Witek RP, Syn WK, et al. Viral factors induce hedgehog pathway activation in humans with viral hepatitis, cirrhosis, and hepatocellular carcinoma. Lab Invest. 2010;90:1690-1703.
41. Bendell JC, Hart LL, Firdaus I, et al. Safety analysis of a randomized phase II trial of hedgehog pathway inhibitor (HPI) GDC-0449 versus placebo with FOLFOX or FOLFIRI and bevacizumab in patients with previously untreated metastatic colorectal cancer (mCRC) [abstract]. J Clin Oncol. 2010;28(5S). Abstract 3530.